Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,612.80
(
-0.46%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.22
(
0.75%
)
Bitcoin
70,691.01
(
1.13%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: DewDiligence post# 172025

Wednesday, 01/01/2014 2:11:59 AM

Wednesday, January 01, 2014 2:11:59 AM

Post# of 257262

GIFT-2—treatment-naïve and treatment-experienced GT2 with and w/o cirrhosis





It's newsworthy ABBV is running a Phase-3 study in GT2 patients. How many GT2 patients have been treated with the 2-DAA combo? What were the SVR rates? Would this study be enough for GT2 labeling in Japan?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now